The effects of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients

Sarafidis, Panteleimon; Lasaridis, Anastasios N.; Hatzistavri, L.; Zebekakis, Pantelis; Tziolas, Ioannis M.; Διαμαντόπουλος, Αθανάσιος

doi:10.1016/j.amjhyper.2004.03.582

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dihydropyridine CCBs, like amlodipine, benidipine, and long-acting nifedipine, were associated with significant improvement of IS measured with a modified insulin suppression test [40]. Studies using the HOMA-IR index to assess the effect of CCBs on IS yielded conflicting results; amlodipine was associated with a significant reduction in IR [35] and lercanidipine showed a trend toward a favorable effect [41], whereas nisoldipine did not significantly affect IS [42•]. Treatment with isradipine up to 6 months resulted in no change in IS [43].…”

Section: Antihypertensive Agents and Insulin Sensitivitymentioning

confidence: 98%

Antihypertensive agents, insulin sensitivity, and new-onset diabetes

Sarafidis

McFarlane²,

Bakris³

2007

Curr Diab Rep

View full text Add to dashboard Cite

The effects of the antihypertensive drugs on carbohydrate metabolism and the development of diabetes have been a major research field for more than two decades. Many clinical studies have investigated the effects of the antihypertensive classes on insulin sensitivity and glycemic control, whereas several observational studies and large outcome trials have examined associations of antihypertensive agents with diabetes incidence. In general, thiazide diuretics and conventional beta blockers decrease insulin sensitivity and increase new-onset diabetes, whereas angiotensin-converting enzyme inhibitors, calcium channel blockers, and angiotensin II receptor blockers have neutral or beneficial effects on these parameters. However, several issues in this field, such as the specific properties of newer agents and the relationship of adverse metabolic outcomes and cardiovascular risk, remain to be fully elucidated. This article presents and evaluates the current knowledge in this important area.

show abstract

Section: Antihypertensive Agents and Insulin Sensitivitymentioning

confidence: 98%

Antihypertensive agents, insulin sensitivity, and new-onset diabetes

Sarafidis

McFarlane²,

Bakris³

2007

Curr Diab Rep

View full text Add to dashboard Cite

show abstract

“…Combination of RAS blockade with a CCB is therefore a strong candidate for dual therapy in patients at high CV and renal risk. Although amlodipine has been the most commonly used CCB in combination therapy, other CCBs such as lercanidipine [39][40][41] and manedipine [42][43][44][45][46] in combination with ACE inhibitors or ARBs have also been shown to provide additional BP lowering and benefits beyond BP lowering. The combination of an ACE inhibitor plus a diuretic, compared with ACE inhibitor alone, provides greater BP reductions and may have a greater preventive effect on stroke [47].…”

Section: Selecting An Appropriate Dual Combination Therapymentioning

confidence: 99%